Registration number: P №011530 / 01 from
Trade name of the drug: WOBENZYM ® WOBENZYM
Dosage Form: enteric-coated tablets (dragees).
Composition: Active substances: Pancreatin 345 prot.
Description: Round biconvex tablets with a smooth surface, with a characteristic odor, painted in red-orange color. Variations in the color intensity of the outer shell from red-orange to red are allowed.
Pharmacotherapeutic group: anti-inflammatory, immunomodulating agent. ATX code E03AH
Pharmacological properties VOBANZIM is a combination of natural enzymes of plant and animal origin. When entering the body, the enzymes are absorbed in the small intestine by resorption of intact molecules and, by binding to transport proteins of the blood, enter the bloodstream. In the future, the enzymes, migrating along the vascular bed and accumulating in the zone of the pathological process, have immunomodulating, anti-inflammatory, fibrinolytic, anti-edema, antiplatelet and secondary analgesic effect. VOBENZIM has a positive effect on the course of the inflammatory process, limits the pathological manifestations of autoimmune and immunocomplex processes, positively affects the indicators of the body’s immunological reactivity. Stimulates and regulates the level of functional activity of monocyte macrophages, natural killer cells, stimulates antitumor immunity, cytotoxic T-lymphocytes, phagocytic activity of cells. Under the influence of VOBENZIMA, the number of circulating immune complexes decreases and membrane deposits of immune complexes are removed from the tissues. VOBENZIM reduces the infiltration of the interstitium by plasma cells. Increases the elimination of protein detritus and fibrin deposits in the area of inflammation, accelerates the lysis of toxic metabolic products and necrotic tissue. Improves resorption of hematomas and edema, normalizes the permeability of the walls of blood vessels.
VOBENZIM reduces the concentration of thromboxane and platelet aggregation. It regulates adhesion of blood cells, increases the ability of red blood cells to change their shape, adjusting their plasticity, normalizes the number of normal discocytes and reduces the total number of activated platelet forms, normalizes blood viscosity, reduces the total number of microaggregates, thus improving microcirculation and rheological properties of blood, as well as supplying tissues oxygen and nutrients.
VOBENZIM reduces the severity of side effects associated with hormonal drugs (hypercoagulation, etc.).
VOBANZIM normalizes lipid metabolism, reduces the synthesis of endogenous cholesterol, increases the content of high-density lipoproteins, reduces the level of atherogenic lipids, improves the absorption of polyunsaturated fatty acids.
VOBENZIM increases the concentration of antibiotics in the blood plasma and inflammation, thus increasing the effectiveness of their use. At the same time, enzymes reduce undesirable side effects of antibiotic therapy (dysbacteriosis), by improving the environment. VOBANZIM regulates the mechanisms of nonspecific protection (production of interferons), thereby showing antiviral and antimicrobial action.
Indications for use Applied in complex therapy of the following diseases:
Prevention microcirculation disorders, post-stress disorders, as well as the breakdown of adaptation mechanisms. Prevention of side effects of hormone replacement therapy, hormonal contraception. In surgical interventions to prevent infectious complications and adhesive disease.
VOBENZIM is recommended for the prevention of infectious complications and improving the quality of life during chemotherapy or radiotherapy. Prevention of viral infections and their complications.
Contraindications Individual intolerance to the drug. Diseases associated with an increased likelihood of bleeding (hemophilia, thrombocytopenia, etc.). Hemodialysis. Children’s age up to 5 years.
Use during pregnancy and lactation Pregnancy and lactation are not a contraindication for the use of the drug, however, pregnant women should take VOBENZIM under the supervision of a physician.
Dosing and Administration Tablets should be taken orally, at least 30 minutes before a meal, without chewing, drinking water (200 ml.). Adults Depending on the activity and severity of the disease, VOBENZIM is taken in a dose of from 3 to 10 tablets 3 times a day. In the first three days of taking the drug, the recommended dose is 3 tablets 3 times a day. With an average disease activity, VOBENZIM is prescribed in a dose of 5-7 tablets 3 times a day for 2 weeks. In the future, the dose of VOBENZIMA should be reduced to 3-5 tablets 3 times a day, a course of 2 weeks. With high disease activity VOBENZIM prescribed in a dose of 7-10 tablets 3 times a day for 2-3 weeks. Further, the dose of VOBANZIMA is reduced to 5 tablets 3 times a day, a course of 2-3 months. In case of chronic long-term current diseases, VOBENZIM can be used according to indications in courses from 3 to 6 months or more. In order to increase the effectiveness of antibiotics and the prevention of dysbacteriosis, VOBENZIM should be applied throughout the entire course of antibiotic therapy in a dose of 5 tablets 3 times a day. After stopping the course of antibiotics to restore the microflora (biocenosis) of the intestine, VOBENZIM should be prescribed 3 tablets 3 times a day for 2 weeks. As a “cover” therapy during chemotherapy and radiation therapy, VOBENZIM should be applied in a dose of 5 tablets 3 times a day until completion of the course of chemotherapy and radiotherapy; to prevent infectious complications, improve the tolerability of basic therapy and improve the quality of life. When applying VOBENZIMA preventively The dose of the drug is 3 tablets 3 times a day, a course of 1.5 months with a repetition of 2-3 times a year.
Children Children from 5 to 12 years old – 6 kg of weight of the child 1 tablet per day. From 12 years old according to the scheme for adults. Dosage and duration of treatment depend on the severity of the disease and are determined by the doctor.
Side effect VOBENZIM well tolerated by patients. In most cases, side effects, withdrawal syndrome, addiction was not observed even with prolonged treatment with high doses. In some cases, there are minor changes in the consistency and smell of feces, skin rash in the form of urticaria, which take place with a decrease in the dose of the drug or withdrawal. If there are other adverse reactions that are not noted in the instructions, it is recommended to stop taking the drug and consult a doctor.
Overdose Cases of overdose of the drug is unknown.
Interaction with other drugs While taking VOBANZIMA with other drugs incompatibility cases are not described.
special instructions In the case of infectious processes, VOBENZIM does not replace antibiotics, but increases their effectiveness by increasing the concentration in the blood plasma and the focus of inflammation. It should be borne in mind that at the very beginning of the drug, the symptoms of the disease may worsen, in such cases, treatment should not be interrupted, but a temporary reduction in the dose of the drug is recommended. The drug is not doping and does not have a negative impact on driving a car and performing work that requires high speed mental and physical reactions.
Release form The tablets are packaged in blisters of 20 pcs. and placed in cardboard boxes of 2, 10 blisters with enclosed instructions for use. Packaging – 800 tablets contains tablets in bottles of high density polyethylene with enclosed instructions.
Storage conditions List B. In a dry dark place at a temperature of 15 to 25 ° C, out of the reach of children.
Shelf life The term is 2.5 years. Do not use after the specified expiration date.
Pharmacy sales terms Over the counter.
Manufacturer MUKOS Pharma GmbH Co., Germany, produced by MUKOS Emulsions GmbH, Germany
For more information contact the General Representative Office of MUKOS Pharma in Russia: